NK-derived exosomes in anti-tumor strategies
Authors:
Open Access
- 9 August 2025
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 418
Abstract
Tumors remain one of the major challenges confronting researchers today. The development of tumor is driven by genetic factors, environmental exposures, and homeostatic disruptions, leading to the transformation of normal cells into malignant ones. Natural killer (NK) cells, a crucial class of immune cells in immunotherapy, can directly recognize and eliminate tumor cells without prior stimulation by tumor antigens. Exosomes derived from NK cells exert anti-tumor effects through multiple mechanisms, including the release of cytotoxic molecules, death receptor ligand-mediated apoptosis, and the secretion of cytokines and other bioactive molecules. However, the therapeutic efficacy of unmodified exosomes is constrained by insufficient active components, suppression by the tumor microenvironment, and a lack of targeting specificity. Drug loading and engineering strategies can enhance their therapeutic potential. In this review, we examine advancements in NK cell-derived exosome (NK-Exos)-based anti-tumor strategies, focusing on studies involving native exosomes, drug-loaded exosomes, and surface-modified exosomes for tumor eradication.Keywords
Funding Information
- Henan Province Medical Science and Technology Research Program (SBGJ202102176)
- Key R&D and Promotion Special Project of Henan Provincial Department of Science and Technology (Project No. 22170021)
This publication has 130 references indexed in Scilit:
- Granzyme A, a Stealth Killer in the MitochondrionCell, 2008
- T cell– and B cell–independent adaptive immunity mediated by natural killer cellsNature Immunology, 2006
- Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological FluidsCurrent Protocols in Cell Biology, 2006
- Granzyme A Induces Caspase-Independent Mitochondrial Damage, a Required First Step for ApoptosisImmunity, 2005
- CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cellsEuropean Journal of Immunology, 2001
- Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subsetBlood, 2001
- Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent MannerJournal of Cell Biology, 1999
- Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death ReceptorsCell, 1998
- Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of ApoptosisCell, 1998
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993